Bolden Therapeutics, Inc., a Providence, R.I.-based biotechnology company developing first-in-class therapeutics to promote neurogenesis for the potential treatment of central nervous system illnesses such as Alzheimer’s disease, closed a $1.5M pre-seed convertible note financing.
The round was led by Resolute Venture Partners, and included investments from Slater Technology Fund, Lifespan Vision Ventures, and multiple angel investors.
This financing provides important support to enable the company to advance its preclinical development of antisense oligonucleotides to promote neurogenesis.
Led by Johnny Page, Co-Founder and CEO, and scientific co-founders, Dr. Justin Fallon and Dr. Ashley Webb, Bolden Therapeutics is developing antisense oligonucleotides to modulate this genetically-validated target, The company has begun testing these antisense oligonucleotide candidates in vivo.
Bolden’s foundational research originated from two Brown University research labs in Providence, RI. The company received two ‘Golden Tickets’ from Biogen, allowing the company to take residence at LabCentral and providing the company with two years of sponsored laboratory space within that innovative ecosystem. Bolden’s research facility is currently located at the Tufts Launchpad | biolabs incubator.
FinSMEs
22/01/2024